Interview by Danielle Edwards; article text by Bryan Mc Govern.


Fleta Solomon, managing director of pharmaceutical grade medical cannabis producer Little Green Pharma, is confident in the investment interest for the Australian cannabis market.

Solomon talked with the Investing News Network (INN) during her time at the MJBizConINT’L event in Toronto. She acted as a panelist in a talk about the potential for global hemp and cannabis opportunities.

Little Green Pharma is a producer of cannabinoid medicine in Australia, a market in which it has approximately 1,000 patients.

“It’s just now that we’re starting to see where Canada was probably at the beginning of 2015, which is that exponential growth in patient numbers,” she said.

While Solomon confirmed many are speculating on the potential for legalization in Australia, she said her company is focusing on the pharmaceutical side of the industry with developments in drug delivery.

“We have a lot of support from investors in Canada but, like I said, we don’t even really need to go outside of Australia, because the Australia investors are very hungry,” Solomon told INN.

The executive said the investor base in Australia is very savvy when it comes to cannabis plays and, at this point, they are aware of the real operating companies.

When asked about the relationship between Canadian companies and Australian ones, Solomon said a variety of local firms elected to secure partnerships with cannabis giants in Canada. Little Green Pharma decided not to do that so as to avoid a connection to the recreational market.

“I think for us our philosophy is the medical space… we just didn’t want to be pigeon holed with us (having) a bigger brother (into) recreational,” she said.

Similarly, the executive added Canadian investors have shown interest for the Australian cannabis investment markets.

“I think investors are very hungry, they’re very supportive. However, we did see an early rise of a number of Australian listed companies that probably listed a bit too soon,” Solomon said.

In September, the firm was able to export locally grown medicinal cannabis product to Germany through a partnership with Cansativa.

Watch the interview above to hear the rest of Solomon’s comments from the cannabis event.

Don’t forget to look for the rest of our coverage of MJBizConINT’L, with exclusive interviews and more insights from the show. You can also follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less